Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Breast Cancer-OFS Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Breast Cancer-OFS Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
Drug Updates
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
By
Loretta Fala
Drug Updates
April 2015, Vol 5, No 3
Read More ›
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
By
Loretta Fala
Drug Updates
March 2015, Vol 5, No 2
Read More ›
Nivolumab (Opdivo): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
Drug Updates
February 2015, Vol 5, No 1
Read More ›
Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved by the FDA for the Treatment of 3 Hematologic Malignancies
By
Lisa A. Raedler, PhD, RPh
Drug Updates
December 2014, Vol 4, No 8
Read More ›
Beleodaq (Belinostat) Receives FDA Approval for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
By
Lisa A. Raedler, PhD, RPh
Drug Updates
November 2014, Vol 4, No 7
Read More ›
Arzerra (Ofatumumab) Receives FDA Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia for Use in Combination with Chlorambucil
By
Lisa A. Raedler, PhD, RPh
Drug Updates
October 2014, Vol 4, No 6
Read More ›
Zykadia (Ceritinib) Approved for the Treatment of Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer
By
Lisa A. Raedler, PhD, RPh
Drug Updates
August 2014, Vol 4, No 5
Read More ›
Imbruvica (Ibrutinib) the First Bruton’s Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Relapsed Chronic Lymphocytic Leukemia
By
Lisa A. Raedler, PhD, RPh
Drug Updates
June 2014, Vol 4, No 4
Read More ›
Page 4 of 4
1
2
3
4